A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 15 Aug 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 23 Jan 2017 Results assessing the feasibility and clinical outcome with intermittent sunitinib dosing in patients with metastatic renal cell carcinoma, published in the Journal of Clinical Oncology.